NaSH相关论文
目的:祛痰活血方是名老中医孙同郊教授多年来总结的经验方,通过前期临床试验发现其能治疗非酒精性脂肪性肝炎（nonalcoholic steatoh......
研究目的:非酒精性脂肪性肝病（Non-alcoholic fatty liver disease,NAFLD）是以肝脏脂肪过度沉积为主要特征的病理综合征,非酒精性脂......
目的：研究组蛋白乙酰转移酶Mof缺失对胚胎小鼠及成年小鼠肝脏功能的影响及相关分子机制方法：1、为了研究Mof在肝脏功能损伤组织中的......
非酒精性脂肪性肝炎（NASH）是非酒精性脂肪性肝病（NAFLD）的炎症亚型，属于肝脏代谢综合征.它是一种全球性的流行病，NAFLD的全球患病率为25%......
目的:研究抑制和激活蛋白（Rap-1）在非酒精性脂肪性肝炎（Non-alcoholic steatohepatitis,简称NASH）中的表达情况,并阐明其在NASH生物学......
G9a是含有经典SET（Su（var）,Enhancer ofzeste,Trithorax）结构域的组蛋白甲基化酶,主要负责常染色质的H3K9me1和H3K9me2,由Ehmt2基因进......
目的:以NLRP3炎症小体通路为靶标,探讨丹参靶向NLRP3炎症小体的活性成分,并揭示其作用机制和靶点,阐明丹参抗炎物质基础和具体作用......
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Reg
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects a third of the population and is a leading cause ......
Interaction of SAMM50-rs738491, PARVB-rs5764455 and PNPLA3-rs738409 Increases Susceptibility to Nona
Background and Aims: Previous studies have reported that the single nucleotide polymorphisms (SNPs) of SAMM50-rs738491, ......
Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephro
Disease-mediated alterations to drug disposition constitute a significant source of adverse drug reactions.Cisplatin(CDD......
Hepatic CDP-diacylglycerol synthase 2 deficiency causes mitochondrial dysfunction and promotes rapid
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies,ranging from steatosis to nonalcoholic st......
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway senses the presence of cytos......
研究背景:非酒精性脂肪性肝炎（NASH）及肝纤维化是当今临床面临的巨大挑战,目前尚无有效防治方法。因此,探寻NASH及肝纤维化防治的新......
学位
目的:通过分析126例非酒精性脂肪性肝病（NAFLD）患者的血清总胆汁酸（TBA）水平和Fibroscan（LSM值）,比较肝组织活动度积分（NAS分级）及肝纤维化......
Nonalcoholic fatty liver disease (NAFLD) affects about a quar-ter of the world\'s population and poses a major health ......
非酒精性脂肪肝（Non-alcoholic fatty liver diseases,NAFLD）是全球公认的最为常见的以发病缓慢、机体代谢改变为特征的肝脏疾病之一......
目的:非酒精性脂肪性肝炎(NASH)是非酒精性脂肪肝较为严重的一种形式,可进展为终末期肝病和肝癌.环氧二十碳三烯酸(EETs)是细胞色......
Cholesterol dyshomeostasis is associated with increased risk of cardiovascular and brain diseases.Our previous studies d......
目的：非酒精性脂肪性肝病(NAFLD)尤其是其关键阶段非酒精性脂肪性肝炎(NASH)已成为全球最重要的公共健康问题之一.病理检查是NASH诊......
目的 非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是一系列由酒精以外的其他因素引起的临床病理综合症,已经成......
Non-alcoholic fatty liver disease(NAFLD)is the hepatic manifestation of obesity and metabolic syndrome,which encompasses......
Fructose metabolism and fructose kinase KHK-C/A are key factors in the development of lipid oversynthesis-promoted metab......
目的探讨泽明红山颗粒对非酒精性脂肪性肝炎(NASH)小鼠肝功能影响及可能机制。方法 SPF级C57BL/6小鼠30只,随机分为对照组(control......
Miners in various blockchain-backed cryptocurrency networks compete to maintain the validity of the underlying distribut......
The major pathological characteristics of NASH are hepatosteatosis,inflammation and fibrosis that could lead to cirr......
Nonalcoholic fatty liver disease(NAFLD),a progressive disease that begins with simple steatosis,may develop to nonal......
目的:探究血清白介素-1受体拮抗剂(IL-1RA)与非酒精性脂肪性肝病(NAFLD)进展的相关性,以及无创性预测诊断NASH的临床价值。方法:选......
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatt
It is estimated that 30%of the adult population in Japan is affected by nonalcoholic fatty liver disease(NAFLD).Fatty ch......
摘要目的本研究评价了Gd-EOB-DTPA增强MRI T1值测量用于非酒精性脂肪肝疾病(NAFLD)动物模型的诊断与分期价值。方法 34只兔子分为......
Nonalcoholic fatty liver disease(NAFLD)is quickly becoming one of the most prominent causes of liver disease worldwide.T......
Non-alcoholic fatty liver disease(NAFLD) is the most frequent cause of liver disease in the Western world. Furthermore, ......
目的探讨双歧杆菌三联活菌胶囊对非酒精性脂肪性肝炎(NASH)患者血清D-乳酸和二胺氧化酶(DAO)水平的影响。方法选取NASH患者88例,随......
目的:比较中药单体化合物小檗碱和噻唑烷二酮类药物罗格列酮对高脂饲料诱导大鼠非酒精性脂肪性肝炎(NASH)的干预作用,探讨小檗碱成......
近年来,以肥胖、糖尿病、脂代谢异常为代表的代谢性疾病在全球范围内不断增加,非酒精性脂肪肝病(nonalcoholic fatty liver diseas......
Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic s
AIM: To investigate the effect of rosuvastatin monotherapy on non-alcoholic steatohepatitis(NASH). At present there is n......
AIM:To study the association between genetic ancestry,non-alcoholic fatty liver disease(NAFLD) metabolic characteristics......
AIM: To examine whether poly-unsaturated fatty acid(PUFA) therapy is beneficial for improving nonalcoholic steatohepatit......
Nonalcoholic fatty liver disease(NAFLD) is the commonest chronic liver disease and includes simple steatosis and nonalco......
Nonalcoholic fatty liver disease(NAFLD) has been identified as one of the most prevalent chronic liver disease in adults......
The growing diffusion of nonalcoholic fatty liver disease(NAFLD) is a consequence of the worldwide increase in the preva......
Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohor
AIM: To investigate the potential burden of nonalcoholic steatohepatitis(NASH) and advanced fibrosis in a hispanic commu......
Red cell distribution width is a measure of deviation of the volume of red blood cells.It is a marker of anisocytosis an......
AIM: To investigate the effects of salvianolic acid B(Sal B) on the morphological characteristics and functions of liver......
Non-alcoholic fatty liver disease(NAFLD) is an emerging health concern in both developed and non-developed world, encomp......
Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical applicat
Heterogeneity in clinical presentation, histological severity, prognosis and therapeutic outcomes characteristic of non-......
Nonalcoholic fatty liver disease(NAFLD), a hepatic manifestation of metabolic syndrome, is the most common chronic liver......
